256 related articles for article (PubMed ID: 29966873)
1. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, in vitro antiproliferative activity and kinase profile of new benzimidazole and benzotriazole derivatives.
Chojnacki K; Wińska P; Skierka K; Wielechowska M; Bretner M
Bioorg Chem; 2017 Jun; 72():1-10. PubMed ID: 28340404
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
4. New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole.
Bretner M; Najda-Bernatowicz A; Łebska M; Muszyńska G; Kilanowicz A; Sapota A
Mol Cell Biochem; 2008 Sep; 316(1-2):87-9. PubMed ID: 18548199
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity.
Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M
Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2.
Najda-Bernatowicz A; Łebska M; Orzeszko A; Kopańska K; Krzywińska E; Muszyńska G; Bretner M
Bioorg Med Chem; 2009 Feb; 17(4):1573-8. PubMed ID: 19168362
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase.
Chojnacki K; Lindenblatt D; Wińska P; Wielechowska M; Toelzer C; Niefind K; Bretner M
Bioorg Chem; 2021 Jan; 106():104502. PubMed ID: 33317841
[TBL] [Abstract][Full Text] [Related]
8. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
9. Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential.
Cozza G; Girardi C; Ranchio A; Lolli G; Sarno S; Orzeszko A; Kazimierczuk Z; Battistutta R; Ruzzene M; Pinna LA
Cell Mol Life Sci; 2014 Aug; 71(16):3173-85. PubMed ID: 24442476
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of novel chiral TBBt derivatives with hydroxyl moiety. Studies on inhibition of human protein kinase CK2α and cytotoxicity properties.
Borowiecki P; Wawro AM; Wińska P; Wielechowska M; Bretner M
Eur J Med Chem; 2014 Sep; 84():364-74. PubMed ID: 25036794
[TBL] [Abstract][Full Text] [Related]
11. The selectivity of inhibitors of protein kinase CK2: an update.
Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
[TBL] [Abstract][Full Text] [Related]
12. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of CK2 inhibitors.
Makowska M; Łukowska-Chojnacka E; Wińska P; Kuś A; Bilińska-Chomik A; Bretner M
Mol Cell Biochem; 2011 Oct; 356(1-2):91-6. PubMed ID: 21750983
[TBL] [Abstract][Full Text] [Related]
14. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.
Sarno S; Mazzorana M; Traynor R; Ruzzene M; Cozza G; Pagano MA; Meggio F; Zagotto G; Battistutta R; Pinna LA
Cell Mol Life Sci; 2012 Feb; 69(3):449-60. PubMed ID: 21720886
[TBL] [Abstract][Full Text] [Related]
15. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I.
Barberis C; Moorcroft N; Arendt C; Levit M; Moreno-Mazza S; Batchelor J; Mechin I; Majid T
Bioorg Med Chem Lett; 2017 Oct; 27(20):4730-4734. PubMed ID: 28947155
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of Novel Acyl Derivatives of 3-(4,5,6,7-Tetrabromo-1
Chojnacki K; Wińska P; Karatsai O; Koronkiewicz M; Milner-Krawczyk M; Wielechowska M; Rędowicz MJ; Bretner M; Borowiecki P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200807
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
Gingipalli L; Block MH; Bao L; Cooke E; Dakin LA; Denz CR; Ferguson AD; Johannes JW; Larsen NA; Lyne PD; Pontz TW; Wang T; Wu X; Wu A; Zhang HJ; Zheng X; Dowling JE; Lamb ML
Bioorg Med Chem Lett; 2018 May; 28(8):1336-1341. PubMed ID: 29559278
[TBL] [Abstract][Full Text] [Related]
19. TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications.
Zień P; Abramczyk O; Domańska K; Bretner M; Szyszka R
Biochem Biophys Res Commun; 2003 Dec; 312(3):623-8. PubMed ID: 14680810
[TBL] [Abstract][Full Text] [Related]
20. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
